Amber Pearson is first patient in the world to benefit from a single stimulator implanted in the brain that effectively controls both epileptic seizures and obsessive-compulsive disorder. Pearson says, “I’m actually present in my daily life and that’s incredible. Before, I was just constantly in my head worrying about my compulsions.” Ahmed Raslan, M.D., says, “It was her idea to say: ‘Well, you’re going into my brain and putting this wire, and I have OCD, so can you just put a wire for OCD?’ And you know, luckily, we took that suggestion seriously.”

A story about cardiac care in Oregon notes the OHSU Knight Cardiovascular Institute is currently involved in 102 active clinical trials and received $12.1 million in research funding during the 2023 fiscal year. In the story, Joaquin Cigarroa, M.D., describes how advances in imaging, genetics and more enable better outcomes for patients with heart issues.

Amber Pearson is first patient in the world to benefit from a single stimulator implanted in the brain that effectively controls both epileptic seizures and obsessive-compulsive disorder. Pearson says, “I’m actually present in my daily life and that’s incredible. Before, I was just constantly in my head worrying about my compulsions.” Ahmed Raslan, M.D., says, “It was her idea to say: ‘Well, you’re going into my brain and putting this wire, and I have OCD, so can you just put a wire for OCD?’ And you know, luckily, we took that suggestion seriously.”

OHSU and others helped UC San Diego design, manufacture, test and analyze sensors that record neuron activity in the brain.

A new study co-authored by scientists at the OHSU Knight Cancer Institute and Pacific Northwest National Laboratory describes how drug resistance develops in some patients with acute myeloid leukemia and how clinicians might someday stop or slow the process. Co-author Jeff Tyner, Ph.D., says: “There is potential for clinical applications to be derived from this work, for example, diagnostics, such as protein biomarkers to predict responses to therapies, and the design of new drug combinations that might outperform current ones.”

A story about an advocacy organization developing an app to help people with substance use disorder find treatment mentions an OHSU study that found Oregon only has about half of the infrastructure and resources it needs to end the addiction crisis.

A story about cardiac care in Oregon notes the OHSU Knight Cardiovascular Institute is currently involved in 102 active clinical trials and received $12.1 million in research funding during the 2023 fiscal year. In the story, Joaquin Cigarroa, M.D., describes how advances in imaging, genetics and more enable better outcomes for patients with heart issues.

An OHSU study finds that access to U.S. residential addiction treatment centers for adolescents is limited and costly.

An editorial by Joanne Noon, Ph.D., RN, recommends the Journal Impact Factor no longer be a factor when considering nominations for nursing research awards: “It is time to move away from evaluating the quality of research based on the journal it was published in and instead evaluate the impact of the research itself.”

A study by OHSU and University of California-Davis Health finds members of historically marginalized communities have a higher risk of hospitalization and more aggressive, life-sustaining treatment near the end of their lives.